08:23 AM EDT, 06/30/2025 (MT Newswires) -- Aurinia Pharmaceuticals ( AUPH ) said Monday its phase 1 study evaluating aritinercept for the potential treatment of autoimmune immune diseases was well tolerated at all dose levels tested.

The biopharmaceutical company said that there were no treatment-related serious adverse events or discontinuations due to treatment-related adverse events. However, adverse events that occurred in more than one subject included injection site reactions, headache, upper respiratory tract infection, and back pain, Aurinia Pharmaceuticals ( AUPH ) said.

The study investigated aritinercept doses of 5 mg, 25 mg, 75 mg, 150 mg, 225 mg and 300 mg and placebo, administered by subcutaneous injection, in 61 healthy subjects.

Aurinia Chief Medical Officer Greg Keenan said the company plans to initiate aritinercept studies for "at least two autoimmune diseases" in H2.

Shares were 1% lower in recent premarket activity.